Myriad Genetics, Inc.
A molecular diagnostics company, Myriad Genetics makes genetic tests that doctors order to gauge hereditary cancer risk, guide drug choices, and screen for prenatal and mental-health conditions. Founded in Salt Lake City in 1991 by a University of Utah geneticist, it became famous for sequencing and patenting the BRCA1 and BRCA2 breast-cancer genes, launching its first test in 1996. The name "myriad" hints at the countless gene possibilities the company explores, and its early gene patents were struck down by the Supreme Court in 2013.
Granted 1.14M · Bought 40.0K
Granted 1.41M · Sold 257.8K
Granted 598.7K
Granted 629.3K
Granted 157.6K · Bought 104.5K
Granted 368.5K · Sold 2.1K
Granted 320.8K
Granted 271.2K
Granted 195.6K · Sold 105.0K
Granted 293.2K
Granted 58.4K · Sold 200
Granted 251.9K
Granted 157.6K · Sold 10.0K
Granted 192.2K · Sold 31.1K
Granted 236.8K
Granted 157.6K
Granted 157.6K · Sold 6.2K
Granted 193.0K
Granted 154.0K · Sold 77.9K
Granted 157.6K · Sold 22.5K
Granted 149.6K · Bought 7.5K
Granted 157.6K · Sold 46.0K
Granted 131.9K · Sold 11.5K
Granted 17.3K
Granted 106.7K
Granted 77.1K
Granted 43.3K
Granted 30.8K
Granted 32.4K · Sold 22.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Raha Samraat S.President and CEO, Director · 13 transactions | — | 1.07M | 1.14M | 40.0K | — |
| Diaz Paul JPresident and CEO, Director · 33 transactions | +122.9% | 891.8Kas of Apr 2025 | 1.41M | — | 257.8K |
| Verratti MarkChief Operating Officer · 53 transactions | +303.5% | 629.6K | 598.7K | — | — |
| Donnelly Brian JChief Commerical Officer · 5 transactions | — | 573.4K | 629.3K | — | — |
| Phanstiel S. LouiseDirector · 8 transactions | +353.5% | 374.8K | 157.6K | 104.5K | — |
| Muzzey DaleChief Scientific Officer · 40 transactions | — | 326.3K | 368.5K | — | 2.1K |
| Fox Jennifer LynneChief Legal Officer · 5 transactions | — | 310.4K | 320.8K | — | — |
| Wheeler Benjamin RichardChief Financial Officer · 10 transactions | — | 298.5K | 271.2K | — | — |
| Riggsbee Richard BryanChief Financial Officer · 30 transactions | -8.4% | 291.8Kas of Jan 2024 | 195.6K | — | 105.0K |
| Solaiman ShereenChief People Officer · 10 transactions | — | 267.8K | 293.2K | — | — |
| Lanchbury Jerry SChief Scientific Officer · 6 transactions | +14.8% | 264.3Kas of Jan 2022 | 58.4K | — | 200 |
| Jampa RajChief Technology Officer · 1 transaction | — | 251.9K | 251.9K | — | — |
| Dreismann HeinrichDirector · 6 transactions | — | 231.1K | 157.6K | — | 10.0K |
| Lambert NicoleChief Operating Officer · 27 transactions | +76.3% | 224.0Kas of Nov 2023 | 192.2K | — | 31.1K |
| Leffler Scott J.Chief Financial Officer · 5 transactions | — | 218.4Kas of Aug 2025 | 236.8K | — | — |
| Skovronsky DanielDirector · 5 transactions | +416% | 195.5K | 157.6K | — | — |
| Newcomer Lee NisleyDirector · 6 transactions | +374.6% | 191.8K | 157.6K | — | 6.2K |
| Haas Kevin RichardChief Technology Officer · 39 transactions | +235.8% | 188.4K | 193.0K | — | — |
| Hart Jayne B.Chief People Officer · 24 transactions | +115.5% | 172.6Kas of Mar 2023 | 154.0K | — | 77.9K |
| Kumar RashmiDirector · 7 transactions | +367.5% | 171.9K | 157.6K | — | 22.5K |
| Bisaro PaulDirector · 6 transactions | — | 157.1K | 149.6K | 7.5K | — |
| Reitan Colleen FDirector · 6 transactions | +276.1% | 152.0K | 157.6K | — | 46.0K |
| Ancona MargaretEVP, Strategy & Transformation · 20 transactions | +325.8% | 127.7K | 131.9K | — | 11.5K |
| Langer DennisDirector · 1 transaction | -10.6% | 106.8Kas of Jun 2022 | 17.3K | — | — |
| Davis Mark StevenDirector · 3 transactions | — | 106.7K | 106.7K | — | — |
| Wong PamelaChief Legal Officer · 11 transactions | — | 65.0Kas of Mar 2024 | 77.1K | — | — |
| Santa EricChief Growth Officer · 4 transactions | +245.5% | 56.7Kas of Apr 2022 | 43.3K | — | — |
| Munk NatalieChief Accounting Officer · 26 transactions | — | 45.2K | 30.8K | — | — |
| Spiegelman Daniel KDirector · 6 transactions | +42.3% | 32.9Kas of Jun 2024 | 32.4K | — | 22.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -441.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.